Physician profile
Terry S Dunn
NPI 1124042346
$14,660.49
in general payments reported to CMS, 2019-2025
36 companies · $426 in 2025
The $426 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,413 · 2020: $585 · 2021: $822 · 2022: $1,301 · 2023: $1,882 · 2024: $5,231 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,585 · Food and Beverage: $2,938 · Consulting Fee: $813 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,585.36 |
| Food and Beverage | $2,937.74 |
| Consulting Fee | $813.00 |
| Education | $201.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $5,201.30 | 2020-2024 | Axonics, Bulkamid |
| Duchesnay USA Incorporated | $3,565.80 | 2019 | |
| Medtronic, INC. | $2,570.93 | 2021-2025 | Interstim, Nuro |
| Astellas Pharma US INC | $823.72 | 2019-2023 | Veozah |
| Pfizer INC. | $374.46 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.18 | 2019-2025 | Xifaxan |
| Medtronic USA, INC. | $315.64 | 2019-2020 | |
| Abbvie INC. | $227.88 | 2020-2025 | Botox |
| Boston Scientific Corporation | $184.32 | 2019-2025 | Axonics |
| Allergan, INC. | $135.04 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $109.73 | 2025 | Gemtesa |
| Therapeuticsmd, INC. | $109.37 | 2019-2020 | |
| Convatec INC. | $85.66 | 2023-2025 | |
| Eisai INC. | $75.84 | 2020-2022 | |
| Myovant Sciences INC. | $53.54 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.01 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Ardelyx, INC. | $33.88 | 2024 | Ibsrela |
| Vertical Pharmaceuticals, LLC | $32.74 | 2019 | |
| Baudax Bio INC. | $32.52 | 2020 | |
| Caldera Medical, INC | $32.30 | 2022 | |
| Exact Sciences Corporation | $29.49 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $25.80 | 2022 | |
| Sunovion Pharmaceuticals INC. | $24.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.60 | 2025 | |
| Lsi Solutions INC | $19.12 | 2024 | Ti-Knot, Running Device |
| Novo Nordisk INC | $18.22 | 2024 | Wegovy |
| Circassia INC. | $17.89 | 2019 | |
| Shire North American Group INC | $16.89 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.50 | 2021 | |
| Organon LLC | $16.34 | 2024-2025 | Nexplanon |
| Urovant Sciences INC | $15.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.96 | 2019 | |
| Coloplast Corp | $13.65 | 2022 | |
| Melinta Therapeutics, LLC | $13.59 | 2019 | |
| Daiichi Sankyo INC. | $13.01 | 2019 | |
| Antares Pharma, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.